Palmitoylation of caspase-6 by HIP14 regulates its activation

Cell Death and Differentiation

Volumn 24, Issue 3, 2017, Pages 433-444

  Skotte, Niels H ^a   Sanders, Shaun S ^a   Singaraja, Roshni R ^a,b,c   Ehrnhoefer, Dagmar E ^a   Vaid, Kuljeet ^a   Qiu, Xiaofan ^a   Kannan, Srinivasaragavan ^d   Verma, Chandra ^d,e,f   Hayden, Michael R ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b AGENCY FOR SCIENCE   (Singapore)

^c Dept Medicine Endocrinol Diabet   (Singapore)

^d BIOINFORMATICS INSTITUTE   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; CASPASE 6; PROTEIN HIP14; UNCLASSIFIED DRUG; HIP14 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; HUNTINGTON CHOREA; MOLECULAR MODEL; MOUSE; NONHUMAN; PALMITOYLATION; PRIORITY JOURNAL; PROTEIN PROCESSING; REGULATORY MECHANISM; ANIMAL; BRAIN; CHLOROCEBUS AETHIOPS; CV-1 CELL LINE; DEFICIENCY; DISEASE MODEL; ENZYME SPECIFICITY; GENETICS; IMMUNOPRECIPITATION; LIPOYLATION; METABOLISM; MOLECULAR DYNAMICS; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; SITE DIRECTED MUTAGENESIS;

ACYLTRANSFERASES; ANIMALS; BRAIN; CASPASE 6; CERCOPITHECUS AETHIOPS; COS CELLS; DIMERIZATION; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; IMMUNOPRECIPITATION; LIPOYLATION; MICE; MOLECULAR DYNAMICS SIMULATION; MUTAGENESIS, SITE-DIRECTED; PROTEIN STRUCTURE, TERTIARY; SUBSTRATE SPECIFICITY;

EID: 85001130038     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2016.139     Document Type: Article

References (77)

1. D'Amelio M, Cavallucci V, Middei S, Marchetti C, Pacioni S, Ferri A, et al. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat Neurosci 2011; 14: 69-76
2. Li Z, Jo J, Jia J-M, Lo S-C, Whitcomb DJ, Jiao S, et al. Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization. Cell 2010; 141: 859-871
3. Park KJ, Grosso CA, Aubert I, Kaplan DR, Miller FD. p75NTR-dependent, myelin-mediated axonal degeneration regulates neural connectivity in the adult brain. Nat Neurosci 2010; 13: 559-566
4. Graham RK, Ehrnhoefer DE, Hayden MR. Caspase-6 and neurodegeneration. Trends Neurosci 2011; 34: 646-656
5. Akpan N, Serrano-Saiz E, Zacharia BE, Otten ML, Ducruet AF, Snipas SJ, et al. Intranasal delivery of caspase-9 inhibitor reduces caspase-6-dependent axon/neuron loss and improves neurological function after stroke. J Neurosci 2011; 31: 8894-8904
6. Ding Z-M, Wu B, Zhang W-Q, Lu X-J, Lin Y-C, Geng Y-J, et al. Neuroprotective effects of ischemic preconditioning and postconditioning on global brain ischemia in rats through the same effect on inhibition of apoptosis. Int J Mol Sci 2012; 13: 6089-6101
7. Berta T, Park C-K, Xu Z-Z, Xie R-G, Liu T, Lü N, et al. Extracellular caspase-6 drives murine inflammatory pain via microglial TNF-a secretion. J Clin Invest 2014; 124: 1173-1186
8. LeBlanc AC. Caspase-6 as a novel early target in the treatment of Alzheimer's disease. Eur J Neurosci 2013; 37: 2005-2018
9. Guo H, Albrecht S, Bourdeau M, Petzke T, Bergeron C, LeBlanc AC. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques and neurofibrillary tangles of Alzheimer's disease. Am J Pathol 2010; 165: 523-531
10. Albrecht S, Bourdeau M, Bennett D, Mufson EJ, Bhattacharjee M, LeBlanc AC. Activation of caspase-6 in aging and mild cognitive impairment. Am J Pathol 2007; 170: 1200-1209
11. Nikolaev A, McLaughlin T, O?Leary DDM, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009; 457: 981-989
12. Banwait S, Galvan V, Zhang J, Gorostiza OF, Ataie M, HuangWet al. C-terminal cleavage of the amyloid-beta protein precursor at Asp664: a switch associated with Alzheimer's disease. J Alzheimers Dis 2008; 13: 1-16
13. Galvan V, Gorostiza OF, Banwait S, Ataie M, Logvinova AV, Sitaraman S, et al. Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci 2006; 103: 7130-7135
14. Galvan V, Zhang J, Gorostiza OF, Banwait S, Huang W, Ataie M, et al. Long-term prevention of Alzheimer's disease-like behavioral deficits in PDAPP mice carrying a mutation in Asp664. Behav Brain Res 2008; 191: 246-255
15. Zhang J, Gorostiza OF, Tang H, Bredesen DE, Galvan V. Reversal of learning deficits in hAPP transgenic mice carrying a mutation at Asp664: a role for early experience. Behav Brain Res 2010; 206: 202-207
16. Group T. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington?s disease chromosomes. The Huntington?s Disease Collaborative Research Group. Cell 1993; 72: 971-983
17. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010; 90: 905-981
18. Graham RK, Deng Y, Carroll J, Vaid K, Cowan C, Pouladi MA, et al. Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo. J Neurosci 2010; 30: 15019-15029
19. Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006; 125: 1179-1191
20. Waldron-Roby E, Ratovitski T, Wang X, Jiang M, Watkin E, Arbez N, et al. Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin. J Neurosci 2012; 32: 183-193
21. Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersén A, et al. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain 2008; 132: 919-932
22. Metzler M, Gan L, Mazarei G, Graham RK, Liu L, Bissada N, et al. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A. J Neurosci 2010; 30: 14318-14329
23. Aharony I, Ehrnhoefer DE, Shruster A, Qiu X, Franciosi S, Hayden MR, et al. A Huntingtinbased peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits. Hum Mol Genet 2015; 24: 2604-2614
24. Wang X-J, Cao Q, Liu X, Wang K-T, Mi W, Zhang Y, et al. Crystal structures of human caspase 6 reveal a new mechanism for intramolecular cleavage self-activation. EMBO Rep 2010; 11: 841-847
25. Baumgartner R, Meder G, Briand C, Decock A, D'arcy A, Hassiepen U, et al. The crystal structure of caspase-6, a selective effector of axonal degeneration. Biochem J 2009; 423: 429-439
26. Klaiman G, Champagne N, LeBlanc AC. Self-activation of Caspase-6 in vitro and in vivo: Caspase-6 activation does not induce cell death in HEK293T cells. Biochem Biophys Acta 2009; 1793: 592-601
27. Kaushal V, Dye R, Pakavathkumar P, Foveau B, Flores J, Hyman B, et al. Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation. Cell Death Differ 2015; 22: 1676-1686
28. Inoue S, Browne G, Melino G, Cohen GM. Ordering of caspases in cells undergoing apoptosis by the intrinsic pathway. Cell Death Differ 2009; 16: 1053-1061
29. Yang C, Kaushal V, Haun RS, Seth R, Shah SV, Kaushal GP. Transcriptional activation of caspase-6 and -7 genes by cisplatin-induced p53 and its functional significance in cisplatin nephrotoxicity. Cell Death Differ 2007; 15: 530-544
30. MacLachlan TK, El-Deiry WS. Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc Natl Acad Sci USA 2002; 99: 9492-9497
31. Ehrnhoefer DE, Skotte NH, Ladha S, Nguyen YTN, Qiu X, Deng Y, et al. p53 increases caspase-6 expression and activation in muscle tissue expressing mutant huntingtin. Hum Mol Genet 2013; 23: 717-729
32. Lee AW, Champagne N, Wang X, Su XD, Goodyer C, LeBlanc AC. Alternatively spliced Caspase-6B isoform inhibits the activation of Caspase-6A. J Biol Chem 2010; 285: 31974-31984
33. Suzuki A, Kusakai G-I, Kishimoto A, Shimojo Y, Miyamoto S, Ogura T, et al. Regulation of caspase-6 and FLIP by the AMPK family member ARK5. Oncogene 2004; 23: 7067-7075
34. Singaraja RR, Huang K, Sanders SS, Milnerwood AJ, Hines R, Lerch JP, et al. Altered palmitoylation and neuropathological deficits in mice lacking HIP14. Hum Mol Genet 2011; 20: 3899-3909
35. Sanders SS, Martin DDO, Butland SL, Lavallée-Adam M, Calzolari D, Kay C, et al. Curation of the Mammalian palmitoylome indicates a pivotal role for palmitoylation in diseases and disorders of the nervous system and cancers. PLoS Comput Biol 2015; 11: e1004405
36. Huang K, El-Husseini A. Modulation of neuronal protein trafficking and function by palmitoylation. Curr Opin Neurobiol 2005; 15: 527-535
37. Vetrivel KS, Meckler X, Chen Y, Nguyen PD, Seidah NG, Vassar R, et al. Alzheimer disease Abeta production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts. J Biol Chem 2009; 284: 3793-3803
38. Cheng H, Vetrivel KS, Drisdel RC, Meckler X, Gong P, Leem JY, et al. S-palmitoylation of gamma-secretase subunits nicastrin and APH-1. J Biol Chem 2009; 284: 1373-1384
39. Drisdel RC, Green WN. Labeling and quantifying sites of protein palmitoylation. Biotech 2004; 36: 276-285
40. Resh MD. Use of analogs and inhibitors to study the functional significance of protein palmitoylation. Methods 2006; 40: 191-197
41. Huang K, Sanders SS, Kang R, Carroll JB, Sutton L, Wan J, et al. Wild-type HTT modulates the enzymatic activity of the neuronal palmitoyl transferase HIP14. Hum Mol Genet 2011; 20: 3356-3365
42. Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, Persichetti F, et al. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet 2000; 9: 2799-2809
43. Forrester MT, Hess DT, Thompson JW, Hultman R, Moseley MA, Stamler JS, et al. Site-specific analysis of protein S-acylation by resin-assisted capture. J Lipid Res 2011; 52: 393-398
44. Ehrnhoefer DE, Skotte NH, Savill J, Nguyen YTN, Ladha S, Cao L-P, et al. A quantitative method for the specific assessment of Caspase-6 activity in cell culture. PLoS One 2011; 6: e27680
45. Resh MD. Membrane targeting of lipid modified signal transduction proteins. Subcell Biochem 2004; 37: 217-232
46. Li S, Li J, Ning L, Wang S, Niu Y, Jin N, et al. In silico identification of protein s-palmitoylation sites and their involvement in human inherited disease. J Chem Inf Model 2015; 55: 2015-2025
47. Warby SC, Doty CN, Graham RK, Carroll JB, Yang YZ, Singaraja RR, et al. Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. Hum Mol Genet 2008; 17: 2390-2404
48. Edgington LE, van Raam BJ, Verdoes M, Wierschem C, Salvesen GS, Bogyo M. An optimized activity-based probe for the study of caspase-6 activation. Chem Biol 2012; 19: 340-352
49. Velázquez-Delgado EM, Hardy JA. Phosphorylation Regulates assembly of the Caspase-6 substrate-binding groove. Structure 2012; 20: 742-751
50. Stanger K, Steffek M, Zhou L, Pozniak CD, Quan C, Franke Y, et al. Allosteric peptides bind a caspase zymogen and mediate caspase tetramerization. Nat Chem Biol 2012; 8: 655-660
51. Heise CE, Murray J, Augustyn KE, Bravo B, Chugha P, Cohen F, et al. Mechanistic and structural understanding of uncompetitive inhibitors of Caspase-6. PLoS One 2012; 7: e50864
52. Müller I, MBAC Lamers, Ritchie AJ, Dominguez C, Munoz-Sanjuan I, Kiselyov A. Structure of human caspase-6 in complex with Z-VAD-FMK: new peptide binding mode observed for the non-canonical caspase conformation. Bioorg Med Chem Lett 2011; 21: 5244-5247
53. Müller I, MBAC Lamers, Ritchie AJ, Park H, Dominguez C, Munoz-Sanjuan I, et al. A new apo-caspase-6 crystal form reveals the active conformation of the apoenzyme. J Mol Biol 2011; 410: 307-315
54. Vaidya S, Velázquez-Delgado EM, Abbruzzese G, Hardy JA. Substrate-induced conformational changes occur in all cleaved forms of caspase-6. J Mol Biol 2011; 406: 75-91
55. Cao Q, Wang XJ, Li LF, Su XD. The regulatory mechanism of the caspase 6 pro-domain revealed by crystal structure and biochemical assays. Acta Cryst 2014; D70: 58-67
56. Yanai A, Huang K, Kang R, Singaraja RR, Arstikaitis P, Gan L, et al. Palmitoylation of huntingtin by HIP14is essential for its trafficking and function. Nat Neurosci 2006; 9: 824-831
57. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Dürr A, Craufurd D, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: crosssectional analysis of baseline data. Lancet Neurol 2009; 8: 791-801
58. Sutton LM, Sanders SS, Butland SL, Singaraja RR, Franciosi S, Southwell AL, et al. Hip14ldeficient mice develop neuropathological and behavioural features of Huntington disease. Hum Mol Genet 2013; 22: 452-465
59. Dagbay K, Eron SJ, Serrano BP, Velázquez-Delgado EM, Zhao Y, Lin D, et al. A multipronged approach for compiling a global map of allosteric regulation in the apoptotic caspases. Meth Enzymol 2014; 544: 215-249
60. Shipston MJ. Ion channel regulation by protein palmitoylation. J Biol Chem 2011; 286: 8709-8716
61. Salaun C, Greaves J, Chamberlain LH. The intracellular dynamic of protein palmitoylation. J Cell Biol 2010; 191: 1229-1238
62. Singaraja RR, Kang MH, Vaid K, Sanders SS, Vilas GL, Arstikaitis P, et al. Palmitoylation of ATP-binding cassette transporter A1 is essential for its trafficking and function. Circ Res 2009; 105: 138-147
63. Huang K, Sanders S, Singaraja R, Orban P, Cijsouw T, Arstikaitis P, et al. Neuronal palmitoyl acyl transferases exhibit distinct substrate specificity. FASEB J 2009; 23: 2605-2615
64. Wong BKY, Ehrnhoefer DE, Graham RK, Martin DDO, Ladha S, Uribe V, et al. Neurobiol Dis 2015; 76: 24-36
65. Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N, et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the huntington disease gene /allele-specific silencing of mutant huntingtin. Mol Ther 2011; 19: 2178-2185
66. Graham RK, Deng Y, Pouladi MA, Vaid K, Ehrnhoefer D, Southwell AL, et al. Caspase-6-resistant mutant huntingtin does not rescue the toxic effects of caspase-cleavable mutant huntingtin in vivo. J Huntingtons Dis 2012; 1: 243-260
67. Weiss A, Abramowski D, Bibel M, Bodner R, Chopra V, DiFiglia M, et al. Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington?s disease. Anal Biochem 2009; 395: 8-15
68. Schroeder T, Barandun J, Flütsch A, Briand C, Mittl PRE, Grütter MG. Specific inhibition of Caspase-3 by a competitive DARPin: molecular mimicry between native and designed inhibitors. Structure 2013; 21: 277-289
69. Case DA, Betz RM, Botello-Smith W, Cerutti DS, Cheatham, III, TE, Darden TA, et al. (2009). AMBER 2009, University of California, San Francisco
70. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983; 79: 926
71. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, Zhang W, et al. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem 2003; 24: 1999-2012
72. Khoury GA, Thompson JP, Smadbeck J, Kieslich CA, Floudas CA. Forcefield PTM: ab initio charge and AMBER forcefield parameters for frequently occurring post-translational modifications. J Chem Theory Comput 2013; 9: 5653-5674
73. Darden T, York D, Pedersen L. Particle mesh Ewald: an Nlog(N) method for Ewald sums in large systems. J Chem Phys 1993; 98: 10089
74. S M, PA K. Settle: an analytical version of the SHAKE and RATTLE algorithm for rigid water models. J Comput Chem 1992; 13: 952-962
75. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996; 14: 33-8-27-8
76. De Lano W. The PyMOL Molecular Graphics System
77. Butland SL, Sanders SS, Schmidt ME, Riechers SP, Lin DTS, Martin DDO, et al. The palmitoyl acyltransferase HIP14 shares a high proportion of interactors with huntingtin: implications for a role in the pathogenesis of Huntington's disease. Hum Mol Genet 2014; 23: 4142-4160